Cancer Institute And Hospital, Chinese Academy Of Medical Sciences

This study tests whether high-dose radiation can control tumors in people with locally advanced or recurrent metastatic breast cancer that has not responded to systemic therapy. Participants receive radical-dose radiotherapy, and those with large tumors (5 cm or more) may get a s…

This early-stage trial tests a new approach to CAR-T therapy where a virus is injected directly into the bloodstream to reprogram a patient's own immune cells to attack cancer. It involves 91 adults with advanced solid tumors who have run out of standard options. The main goal is…

This early-phase study tests an inhaled mRNA immunotherapy for adults with advanced lung cancer or solid tumors that have spread to the lungs. The treatment is given as a dry powder through an inhaler. The main goal is to check safety and find the best dose, with 60 participants …

This early study tests a new cell therapy called QH101 for people with solid tumors that have spread to the brain, spinal cord, or surrounding membranes. The therapy uses specially engineered immune cells designed to better recognize and attack cancer cells. The main goals are to…

This study tests a risk-based approach to radiation after breast-conserving surgery for early breast cancer. Depending on individual risk, patients receive either whole-breast or partial-breast radiation in fewer, larger doses (hypofractionation). The goal is to maintain cancer c…

This early-stage trial is testing two experimental drugs, OVV-01 and AK112, in 30 people with advanced solid tumors that have not responded to standard treatments. OVV-01 is given both into a vein and directly into the tumor, while AK112 is given into a vein. The main goals are t…

This Phase 2 trial tests two drugs, OVV-01 and AK112, given together every two weeks to 40 adults with advanced soft tissue sarcoma that has not responded to standard treatments. The main goal is to see if the combination can shrink tumors safely. Researchers will also measure ho…

This study tests whether adding the cholesterol drug atorvastatin to standard targeted therapy (axitinib) and immunotherapy (toripalimab) can help people with advanced kidney cancer who are not responding well to treatment. The drug combination is guided by lab tests on patient-d…

This study looks at whether adding an immunotherapy drug (penpulimab) to standard pre-surgery radiation and a targeted therapy (anlotinib) can help people with soft tissue sarcoma live longer without the cancer coming back. About 274 adults with intermediate- to high-grade sarcom…

This phase 3 trial tests a new type of radiotherapy that uses daily MRI scans to precisely target brain metastases from lung cancer. The approach, called MR-guided adaptive radiotherapy, adjusts the radiation dose based on real-time tumor changes. Researchers hope it will improve…

This early-phase study tests a new experimental drug (BRII-5395) combined with two approved cancer treatments (sintilimab and bevacizumab) in about 21 adults with advanced liver cancer linked to chronic hepatitis B. The main goal is to check safety and find the right dose, while …

This study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with a large, advanced type of lung cancer (stage III NSCLC) live longer without the cancer growing. About 204 adults aged 18-75 with tumors at least 5 cm wide or lymph nodes at least …

This phase II trial tests a drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has worsened after at least one prior treatment. The drug is given by IV every two weeks. The main goal is to see if it can shrink tumors, and researchers will also t…

This phase 2 trial tests a combination of the drug zorifertinib plus chemotherapy delivered directly into the fluid around the brain and spine. It is for people with a specific type of lung cancer (NSCLC with EGFR mutation) whose cancer has spread to the lining of the brain and s…

This early-stage trial tests a new drug called BR101 in 10 people with multiple myeloma that has returned or not responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at whether the drug helps shrink the ca…

This phase 2 trial tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemoradiotherapy can help people with locally advanced esophageal cancer whose initial chemo-immunotherapy did not work. About 40 participants will receive the treatment…

This phase II trial is testing a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) for people with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this 3-week course is safe and effective at controlling the cancer while pos…

This early study tests a new drug called MTM-H-001 in 69 adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, while also seeing if it can shrink tu…

This study tests a drug called darolutamide, with or without hormone therapy (ADT), given before surgery for high-risk localized prostate cancer. Sixty men will be split into two groups: one gets darolutamide alone, the other gets darolutamide plus ADT for 3-6 months before robot…

This early-stage trial tests a new gene-editing drug called EDB-102 in 15 people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to standard targeted therapy. The drug uses CRISPR technology to target and disable a specific cancer-caus…

This study tests whether adding immunotherapy (toripalimab) to standard chemotherapy before surgery can improve outcomes for people with muscle-invasive bladder cancer. About 30 participants will receive the combination therapy, and researchers will monitor how the tumor and immu…

This study tests whether adding an experimental immunotherapy (Aitua Combination Antibody) to standard chemotherapy can help shrink advanced ovarian cancer more effectively before surgery. About 82 women with stage IIIC-IV high-grade serous ovarian cancer who cannot have optimal …

This Phase 2 trial tests whether adding the experimental drug QL1706 to standard platinum chemotherapy helps people with advanced triple negative breast cancer live longer without their disease getting worse. About 78 adults who have already had one or two prior treatments will b…

This early-phase trial tests a new type of cell therapy called CAR-Macrophages in 20 adults with advanced solid tumors. The immune cells are modified to target specific markers on cancer cells (HER2, PSMA, FAP) and are given by IV. The main goals are to check safety, find the bes…

This trial is testing whether giving a special type of radiation (ultra-hypofractionated) along with immunotherapy before surgery is safe and feasible for people with retroperitoneal sarcoma. The study will enroll 28 participants. The main goal is to see how many patients have co…

This phase 3 trial will test if women with intermediate-risk breast cancer can safely skip radiation to the lymph nodes after surgery. About 3,142 participants will be randomly assigned to receive either standard radiation to the breast or chest wall plus lymph nodes, or radiatio…

This early study tests a new treatment called CAT-101, which uses a patient's own immune cells (dendritic cells) loaded with a cancer protein (mKRAS) to help the body fight tumors. It is for people with advanced pancreatic cancer or other solid tumors that have a specific KRAS mu…

This study looks at whether a smaller lung surgery after immunotherapy works as well as the standard larger surgery for people with stage II-IIIB non-small cell lung cancer. About 354 patients whose tumors shrank with immunotherapy will choose either a limited or conventional sur…

This Phase 2 trial tests whether a new drug combination (fruquintinib plus trifluridine/tipiracil) works better than a standard combo (bevacizumab plus trifluridine/tipiracil) for people with advanced colorectal cancer that has not responded to standard chemotherapy. About 292 ad…

This early-phase trial is testing a combination of two drugs—a targeted pill (Glecirasib) and an immunotherapy infusion (Ivonescimab)—as a first treatment for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The study will first find the saf…

This phase II trial tests whether adding the drugs SHR-A1811 and/or adebrelimab to standard chemotherapy can improve outcomes for people with HR-positive, HER2-low early-stage breast cancer. About 249 participants will receive either chemo alone, chemo plus adebrelimab, or a sequ…

This study tests several new anti-cancer drugs and technologies in 600 people with rare solid tumors that have spread or cannot be removed. Participants will receive treatments matched to their tumor's unique genetic profile. The goal is to see if these therapies are safe and shr…

This phase III trial tests a personalized approach for HER2-positive breast cancer, where treatment is adjusted based on early response (ctDNA and imaging). The goal is to reduce chemotherapy side effects without compromising effectiveness. The study will enroll 2000 women with e…

This Phase 2 trial compares two approaches for locally advanced cervical cancer: standard chemoradiotherapy versus a newer strategy of chemotherapy plus immunotherapy (sintilimab) before surgery. The study will enroll 180 people and track how long they live without the cancer get…

This study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy, with or without a blood-vessel-blocking drug, in 25 women whose recurrent or metastatic cervical cancer has worsened after prior PD-1/PD-L1 treatment. The goal is to see ho…

This study tests whether adding radiation before surgery to standard chemotherapy can shrink tumors more effectively in people with locally advanced breast cancer. It includes 50 participants with Luminal or triple-negative subtypes who did not respond well to initial chemo. The …

This phase 2 trial tests a combination of three drugs—sintilimab, surufatinib, and temozolomide—in 32 people with advanced neuroendocrine carcinoma that has worsened after prior treatment. The goal is to see if the combination can shrink tumors and control the disease. Participan…

This study tests whether a traditional Chinese medicine formula, Wenyang Tongbi Granules, can reduce nerve pain and numbness caused by chemotherapy. 144 adults with breast or colorectal cancer who develop hand-foot tingling or pain during chemo will receive either the herbal gran…

This study tests if a daily protein drink can lower the chance of severe mouth sores caused by radiation therapy in people with head and neck cancer. About 504 adults will either get the protein supplement or a placebo drink without protein during their radiation treatment. The g…

This study looks at whether it's safe to avoid placing a tube through the nose into the stomach after minimally invasive pancreatic surgery. About 200 adults having this surgery will be randomly assigned to either get the tube or not. The goal is to see if skipping the tube reduc…

This study looks at where cancer spreads to lymph nodes in people with colon or rectal cancer. Researchers will examine tissue from 1200 patients who had surgery to remove their cancer. The goal is to find patterns that could help doctors better plan treatment in the future.

This study will look back at medical records of 300 people with advanced non-small cell lung cancer (NSCLC) whose disease got worse after first-line immunotherapy. Researchers want to see which second-line treatments were used and how well they worked in real-world practice. The …

This study will test a new AI tool called BaiXiaoAi that helps cancer patients, their families, and their doctors stay connected. About 300 adults with cancer will join a special WeChat group where the AI answers questions and shares helpful information. The goal is to see if the…

This study looks at kidney cancer tumors that have multiple small nodules inside them. Researchers will take samples from 10 patients and use advanced gene mapping to see if the nodules are different. They will also grow tiny 3D tumor models in the lab to test how they respond to…